Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1

Cancer

Volumn 88, Issue 9, 2000, Pages 2010-2021

  Fralix, Kimberly D ^a   Ahmed, Mansoor M ^b   Mattingly, Cynthia ^b   Swiderski, Carol ^b   McGrath, Patrick C ^b   Venkatasubbarao, Kolaparthi ^a   Kamada, Nanao ^c   Mohiuddin, Mohammed ^b   Strodel, William E ^a   Freeman, James W ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GROWTH REGULATION; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ALLELES; ANIMALS; CELL DIVISION; CODON; CULTURE MEDIA; DNA-BINDING PROTEINS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENOTYPE; POINT MUTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0034192220     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5     Document Type: Article

References (52)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Stat Bite: U.S. pancreatic cancer survival rates by age. J Natl Cancer Inst 1999;91:1190.
3. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R. Surgery for exocrine pancreatic cancer: who are the 5-and 10-year survivors? Oncology 1995;52:353-9.
4. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
5. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and k-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-91.
6. Kolaparthi V, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR Jr, Salhalo KF, McGrath P, Strodel W, Freeman JW. Differential expression of transforming growth factor receptors in human pancreatic adenocarcinoma. Anticancer Res 2000. In press.
7. Freeman JW, Mattingly CA, Strodel WE. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF β type II receptor. J Cell Phys 1995;165:155-63.
8. Howell GM, Sun LZ, Ziober BL, Wu SP, Brattain MG. The role of growth regulatory aberrations in progression of human colon carcinoma. Cancer Metastasis Rev 1993;12:275-86.
9. Wu SP, Sun LZ, Willson JVK, Humphrey L, Kerbel R, Brattain MG. Repression of autocrine transforming growth factor β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Diff 1993;4:115-23.
10. Wu SP, Theodorescu D, Kerbel RS, Willson JVK, Mulder KM, Humphrey LE, et al. TGFβ1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992;116:187-96.
11. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
12. Myeroff LL, Parsons R, Kim SK, Hedrick L, Cho KR, Orth K, et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55:5545-7.
13. Parsons R, Myeroff L, Liu B, James KV, Markowitz SD, Kinzler K, et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 1995;55:5548-50.
14. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gensnode J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55:3982-7.
15. Kadin M, Cavaille-Coll M, Gertz R, Massague J, Chefetz S, George D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci U S A 1994;91:6002-6.
16. Villanueva A, Garcia C. Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78.
17. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, et al. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.
18. Freiss H, Yamanaka Y, Buchler M, Beger HG, Kobrin MS, Baldwin RL, et al. Enhanced expression of the type II transforming growth factor β receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
19. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGFβ signaling pathways. Nature 1996;33:832-6.
20. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
21. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang Y, et al. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error positive colon carcinoma cells. J Biol Chem 1995;270:22044-9.
22. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
23. Barbacid M. ras genes. Ann Rev Biochem 1987;56:779-827.
24. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-9.
25. Healicon RM, Westley BR, May FE. Isolation and characterization of an estrogen-responsive breast-cancer cell line, EFF-3. Int J Cancer 1993;53:388-94.
26. Ahmed MM, Bharadwaj TPR, Sethuraman S, Chandy M, Pushpa V, Kamada N. Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet 1993;65:12-20.
27. F Mitelman, editor. ISCN: an international system for human cytogenetic nomenclature. Published in collaboration with Cytogenet Cell Genet. Basel: Karger, 1995.
28. Mohiuddin MD, Ahmed MM, Venkatasubbarao K. c-Ki-ras mutations in peripheral blood of pancreatic cancer patients: a marker for early tumor metastasis. Int J Radiat Oncol Biol Phys 1996;34:161-6.
29. Hopman AH, Ramaekers FCS, Raap AK, Beck IL, Devilee P, van der Ploeg M, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 1988;89:307-16.
30. Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP Jr., Sells SF, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 1996;271:29231-7.
31. Venkatasubbarao K, Ahmed MM, Swiderski C, Harp C, Lee EY, McGrath P, et al. Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas. Genes Chromosomes Cancer 1998;22: 138-44.
32. Wood DP Jr., Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastasis in patients with prostate cancer. Cancer 1994;74:2533-40.
33. Redston MS, Caldas C, Seymour AB, Hurban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
34. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
35. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
36. de Fromentel CC, Soussi T. p53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
37. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
38. Roberts AB, Sporn MB. The transforming growth factor-betas. In: Sporn MB, Roberts AB. Peptide growth factors and their receptors. Heidelberg: Springer Verlag, 1991:419-72.
39. Massague J. The transforming growth factor-β family. Ann Rev Cell Biol 1990;6:597-641.
40. Ziober BL, Willson JVK, Humphrey LE, Childress-Fields K, Brattain MG. Autocrine transfoming growth factor-α is associated with progression of transformed properties in human colon cancer cells. J Biol Chem 1993;268:691-8.
41. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995;55: 4670-5.
42. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-4.
43. Bos JL. Ras oncogenes in human cancer: a review [published erratum appears in Cancer Res 1990;50:1352]. Cancer Res 1989;49:4682-9.
44. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997;37:143-66.
45. Rideout WM III, Coetzee GA, Olumi AF, Jones PA. 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-90.
46. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-30.
47. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
48. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987;329:219-22.
49. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunayake I, et al. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994;269:26449-55.
50. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, et al. Genetic changes in the transforming growth factor β (TGF β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF β. Proc Natl Acad Sci USA 1994;91:8772-6.
51. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB. Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 1991;14(Suppl 2):515-20.
52. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58:5329-32.